April 1997
Volume 38, Issue 5
Free
Articles  |   April 1997
Use of topical FK506 in a corneal graft rejection model in Lewis rats.
Author Affiliations
  • N Hikita
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
  • J S Lopez
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
  • C C Chan
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
  • M Mochizuki
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
  • R B Nussenblatt
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
  • M D de Smet
    Department of Ophthalmology, Kurume University School of Medicine, Japan.
Investigative Ophthalmology & Visual Science April 1997, Vol.38, 901-909. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N Hikita, J S Lopez, C C Chan, M Mochizuki, R B Nussenblatt, M D de Smet; Use of topical FK506 in a corneal graft rejection model in Lewis rats.. Invest. Ophthalmol. Vis. Sci. 1997;38(5):901-909.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: To evaluate the immunosuppressive effect of topical FK506 on allograft corneal rejection in rats. METHODS: Lewis rats were used as recipients and Fisher rats as corneal graft donors. In Experiment 1, all rats received intraperitoneally FK506 (0.3 mg/kg per day) for 7 days to ensure equal baseline parameters. The rats then were assigned randomly to treatment with topical 0.3% FK506 or vehicle alone. In another set of experiments, rats were treated only with topical treatment. The grafts were inspected by clinical evaluation. Corneas obtained at the time of maximum rejection were used for histology and immunohistochemistry. RESULTS: The selected combination of rat strains caused 100% graft rejection in untreated animals within 2 weeks after the penetrating keratoplasty. In the treated animals, rejection was delayed until the end of topical therapy. One third of corneal grafts remained clear until day 30. Histologic and immunohistochemical studies confirmed the clinical evaluations. Untreated rat corneas had a large number of infiltrating helper-inducer T cells, macrophages, interleukin-2 receptor-expressing cells, and Ia-antigen-expressing cells. At the same timepoint, topically treated corneas showed a limited inflammatory response characterized by a 2/3 reduction in the number of infiltrating helper and cytotoxic cells, and a five-fold decrease in the expression of class I and class II major histocompatibility antigens. CONCLUSIONS: Topical FK506 treatment is an effective way of preventing corneal graft rejection in the Lewis rat corneal graft model. It shows promise as a drug to prevent corneal graft rejection in humans.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×